Verastem (VSTM) Stock Forecast & Price Target

Verastem is viewed favorably because its late-stage pipeline combines a commercially meaningful approved asset with a potentially best-in-class KRAS G12D program, creating both current revenue-floor support and substantial pipeline upside. The 2025 launch of AVMAPKI FAKZYNJA in LGSOC addresses an unmet-need market of approximately 1K-2K new patients per year, while full data from FRAME and RAMP 201 support its clinical potential and the cited combined worldwide revenue opportunity exceeds $1.3B across indications. Meanwhile, VS-7375 has shown strong efficacy and manageable safety in TARGET-D 101 and GenFleet’s phase 2 studies, including a 44% ORR in 54 CRC patients and a 71% ORR in 24 1L PDAC patients, reinforcing confidence in combination use and phase III success.

Verastem is viewed negatively because its valuation hinges on a narrow, clinical-stage asset base while lacking sizable and definitive randomized data for Avmapki Fakzynja, leaving commercial traction, durability of efficacy, and safety as unresolved questions. The company’s key risk is that failure of RAMP-301, slow launch progression, or a safety signal could compress value toward net cash with minimal pipeline value, especially since LGSOC is a small indication and patient enrollment may be difficult. Beyond the lead program, most expansion opportunities remain early stage and unproven, with competition, data transparency, and broader clinical-trial execution risks limiting confidence in long-term upside.